5 results on '"Lisa France"'
Search Results
2. The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions
- Author
-
Steve N. Georas, Rosalind J. Wright, Anastasia Ivanova, Elliot Israel, Lisa M. LaVange, Praveen Akuthota, Tara F. Carr, Loren C. Denlinger, Merritt L. Fajt, Rajesh Kumar, Wanda K. O’Neal, Wanda Phipatanakul, Stanley J. Szefler, Mark A. Aronica, Leonard B. Bacharier, Allison J. Burbank, Mario Castro, Laura Crotty Alexander, Julie Bamdad, Juan Carlos Cardet, Suzy A.A. Comhair, Ronina A. Covar, Emily A. DiMango, Kim Erwin, Serpil C. Erzurum, John V. Fahy, Jonathan M. Gaffin, Benjamin Gaston, Lynn B. Gerald, Eric A. Hoffman, Fernando Holguin, Daniel J. Jackson, John James, Nizar N. Jarjour, Nicholas J. Kenyon, Sumita Khatri, John P. Kirwan, Monica Kraft, Jerry A. Krishnan, Andrew H. Liu, Mark C. Liu, M. Alison Marquis, Fernando Martinez, Jacob Mey, Wendy C. Moore, James N. Moy, Victor E. Ortega, David B. Peden, Emily Pennington, Michael C. Peters, Kristie Ross, Maria Sanchez, Lewis J. Smith, Ronald L. Sorkness, Michael E. Wechsler, Sally E. Wenzel, Steven R. White, Joe Zein, Amir A. Zeki, Patricia Noel, Dean Billheimer, Eugene R. Bleecker, Emily Branch, Michelle Conway, Cori Daines, Isaac Deaton, Alexandria Evans, Paige Field, Dave Francisco, Annette T. Hastie, Bob Hmieleski, Jeffrey O. Krings, Yanqin Liu, Janell L. Merchen, Deborah A. Meyers, Nirushan Narendran, Stephen P. Peters, Anna Pippins, Matthew A. Rank, Ronald Schunk, Raymond Skeps, Benjamin Wright, Tina M. Banzon, Lisa M. Bartnikas, Sachin N. Baxi, Vishwanath Betapudi, Isabelle Brick, Conor Brockway, Thomas B. Casale, Kathleen Castillo-Ruano, Maria Angeles Cinelli, Elena Crestani, Amparito Cunningham, Megan Day-Lewis, Natalie Diaz-Cabrera, Angela DiMango, Brittany Esty, Eva Fandozzi, Jesse Fernandez, Elizabeth Fitzpatrick, Victoria E. Forth, Katarina Gentile, David Gubernick, Seyni Gueye-Ndiaye, Sigfus Gunnlaagsson, Marissa Hauptmann, Stephanie N. Hudey, Donya S. Imanirad, Tiffani Kaage, Nicholas Kolinsky, Brenna LaBere, Peggy Sue Lai, Meghan Le, Dennis K. Ledford, Richard Lockey, Margee Louisias, Andrew J. Macginnitie, Michelle C. Maciag, Allison O’Neill, Amber N. Pepper, Perdita Permaul, Mya Pugh, Dianna Queheillalt, Tarnjot Saroya, William Sheehan, Catherine Smith, Carmela Socolovsky, Else Treffeisen, Lorenzo Trippa, Abigail Tulchinsky, Christina Yee, Tina Carter, Jun Fu, Vanessa Garcia, Jenny Hixon, Carly Jackson, Yuan Ji, Ravi Kalhan, Opinderjit Kaur, Grace Li, Melanie M. Makhija, Spring Maleckar, Edward T. Naureckas, Anju T. Peters, Valerie Press, Mehreen Qureshi, Paul A. Reyfman, Sharon R. Rosenberg, Dominika Ryba, Jianrong Sheng, Ben Xu, Rafeul Alam, Darci Anderson, Sonya Belimezova, Jennifer Bitzan, Geoffrey Chupp, Brian J. Clark, Lauren Cohn, Margaret Hope Cruse, Jean Estrom, Leah Freid, Jose Gomez Villalobos, Nicole Grant, Vamsi P. Guntur, Carole Holm, Christena Kolakowski, Laurie A. Manka, Naomi Miyazawa, Juno Pak, Diana M. Pruitt, Sunita Sharma, Allen D. Stevens, Kisori Thomas, Brooke Tippin, Karissa Valente, Cynthia L. Wainscoat, Michael P. White, Daniel Winnica, Shuyu Ye, Pamela L. Zeitlin, Julia Bach, Joshua Brownell, Lauren Castro, Julie DeLisa, Sean B. Fain, Paul S. Fichtinger, Heather Floerke, James E. Gern, Vinay Goswamy, Jenelle Grogan, Wendy Hasse, Rick L. Kelley, Danika Klaus, Stephanie LaBedz, Paige Lowell, Andrew Maddox, Sameer K. Mathur, Amanda McIntyre, Lourdes M. Norwick, Sharmilee M. Nyenhuis, Matthew J. O’Brien, Tina Palas, Andrea A. Pappalardo, Mark Potter, Sima K. Ramratnam, Daniel L. Rosenberg, Eric M. Schauberger, Mark L. Schiebler, Angela Schraml, Mohamed Taki, Matthew C. Tattersall, Jissell Torres, Lori Wollet, Simon Abi-Saleh, Lisa Bendy, Larry Borish, James F. Chmiel, Aska Dix, Lisa France, Rebecca Gammell, Adam Gluvna, Brittany Hirth, Bo Hu, Elise Hyser, Kirsten M. Kloepfer, Michelle Koo, Nadia L. Krupp, Monica Labadia, Joy Lawrence, Laurie Logan, Angela Marko, Brittany Matuska, Deborah Murphy, Rachel Owensby, Erica A. Roesch, Don B. Sanders, Jackie Sharp, W. Gerald Teague, Laura Veri, Kristin Wavell Shifflett, Matt Camiolo, Sarah Collins, Jessa Demas, Courtney Elvin, Marc C. Gauthier, Melissa Ilnicki, Jenn Ingram, Lisa Lane, Seyed Mehdi Nouraie, John B. Trudeau, Michael Zhang, Jeffrey Barry, Howard Brickner, Janelle Celso, Matejka Cernelc-Kohan, Damaris Diaz, Ashley Du, Sonia Jain, Neiman Liu, Yusife Nazir, Julie Ryu, Pandurangan Vijayanand, Rogelio Almario, Ariana Baum, Kellen Brown, Marilynn H. Chan, Barbara Gale, Angela Haczku, Richart W. Harper, Raymond Heromin, Celeste Kivler, Brooks T. Kuhn, Ngoc P. Ly, Paula McCourt, Xavier Orain, Audrey Plough, Karla Ramirez, Ellese Roberts, Michael Schivo, Amisha Singapuri, Tina Tham, Daniel Tompkins, Patricia Michelle Twitmyer, Jade Vi, Jarron Atha, Jennifer Bedard, Jonathan S. Boomer, Andrew Chung, Vanessa Curtis, Chase S. Hall, Emily Hart, Fatima Jackson, Pamela Kemp, Sharli Maxwell, Maggie Messplay, Crystal Ramirez, Brynne Thompson, Ashley Britt, Hope Bryan, Nathan M. Gotman, Yue Jiang, Michael R. Kosorok, David T. Mauger, Kelsey Meekins, Jeanette K. Mollenhauer, Sarah Moody, Cheyanne Ritz, Stefanie Schwartz, Chalmer Thomlinson, and Nicole Wilson
- Subjects
Severe asthma ,Exacerbation ,Allergy ,Disease ,non-type 2 asthma ,Severity of Illness Index ,asthma exacerbation ,Clinical Protocols ,Immunology and Allergy ,Precision Medicine ,Tomography ,Lung ,education.field_of_study ,X-Ray Computed ,Asthma Control Questionnaire ,Research Design ,Respiratory ,biomarker ,medicine.medical_specialty ,precision medicine ,Population ,Advisory Committees ,Clinical Trials and Supportive Activities ,Immunology ,patient advisory committee ,Natural history of disease ,Article ,Clinical Trials, Phase II as Topic ,Clinical Research ,medicine ,Humans ,type 2 asthma ,Clinical Trials ,Intensive care medicine ,education ,PrecISE Study Team ,Disease burden ,Asthma ,adaptive clinical trial design ,non–type 2 asthma ,business.industry ,Phase II as Topic ,medicine.disease ,Precision medicine ,respiratory tract diseases ,Good Health and Well Being ,business ,Tomography, X-Ray Computed ,Biomarkers - Abstract
Asthma is a heterogeneous disease, with multiple underlying inflammatory pathways and structural airway abnormalities that impact disease persistence and severity. Recent progress has been made in developing targeted asthma therapeutics, especially for subjects with eosinophilic asthma. However, there is an unmet need for new approaches to treat patients with severe and exacerbation-prone asthma, who contribute disproportionately to disease burden. Extensive deep phenotyping has revealed the heterogeneous nature of severe asthma and identified distinct disease subtypes. Acurrent challenge in the field is to translate new and emerging knowledge about different pathobiologic mechanisms in asthma into patient-specific therapies, with the ultimate goal of modifying the natural history of disease. Here, we describe the Precision Interventions for Severe and/or Exacerbation-Prone Asthma (PrecISE) Network, a groundbreaking collaborative effort of asthma researchers and biostatisticians from around the United States. The PrecISE Network was designed to conduct phase II/proof-of-concept clinical trials of precision interventions in the population with severe asthma, and is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health. Using an innovative adaptive platform trial design, the PrecISE Network will evaluate up to 6 interventions simultaneously in biomarker-defined subgroups of subjects. We review the development and organizational structure of the PrecISE Network, and choice of interventions being studied. We hope that the PrecISE Network will enhance our understanding of asthma subtypes and accelerate the development of therapeutics for severe asthma.
- Published
- 2022
3. Scattering paths in test optical bench for LISA mission
- Author
-
Marco Nardello, Michel Lintz, Christelle Buy, null on behalf of the LISA-France collaboration, Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux (ARTEMIS), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire des deux Infinis de Toulouse (L2IT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), CNES, B. Lee, C. Mazzali, K. Corwin, and R. Jason Jones, and LISA mission
- Subjects
Physics ,Heterodyne ,Test bench ,stray light ,business.industry ,Stray light ,Scattering ,scattered light ,interferometry ,01 natural sciences ,law.invention ,Power (physics) ,scattering paths ,010309 optics ,Interferometry ,[SPI]Engineering Sciences [physics] ,Optics ,law ,0103 physical sciences ,[SPI.OPTI]Engineering Sciences [physics]/Optics / Photonic ,LISA mission ,Scattered light ,010306 general physics ,business ,Beam splitter - Abstract
on behalf of the LISA-France collaboration; International audience; Scattered light can disrupt heterodyne measurements in the ZIFO test bench for LISAmission. This study shows a method to find all possible scattering paths and calculate their power, confirming the feasibility of the system.
- Published
- 2020
4. Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation
- Author
-
Wanda Phipatanakul, David T. Mauger, Theresa W. Guilbert, Leonard B. Bacharier, Sandy Durrani, Daniel J. Jackson, Fernando D. Martinez, Anne M. Fitzpatrick, Amparito Cunningham, Susan Kunselman, Lisa M. Wheatley, Cindy Bauer, Carla M. Davis, Bob Geng, Kirsten M. Kloepfer, Craig Lapin, Andrew H. Liu, Jacqueline A. Pongracic, Stephen J. Teach, James Chmiel, Jonathan M. Gaffin, Matthew Greenhawt, Meera R. Gupta, Peggy S. Lai, Robert F. Lemanske, Wayne J. Morgan, William J. Sheehan, Jeffrey Stokes, Peter S. Thorne, Hans C. Oettgen, Elliot Israel, Lisa Bartnikas, David Kantor, Perdita Permaul, Nicole Akar-Ghibril, Mehtap Haktanir-Abul, Sigfus Gunnalaugsson, Brittany Esty, Elena Crestani, Michelle Maciag, Marissa Hauptman, Sachin N. Baxi, Elizabeth Burke-Roberts, Margee Louisias, Tina Banzon, Saddiq Habiballah, Alan Nguyen, Tregony Simoneau, Samantha Minnicozzi, Elsa Treffeisen, Brenna LaBere, Mia Chandler, Manoussa Fanny, Anna Cristina Vasquez-Muniz, Vanessa Konzelman, Giselle Garcia, Sullivan Waskosky, Anna Ramsey, Ethan Ansel-Kelly, Elizabeth Fitzpatrick, Vaia Bairaktaris, Jesse Fernandez, Brianna Hollister, Owen Lewis, Masai McIntosh, Sigrid Almeida, Carolyn Kercsmar, Karen McDowell, Cassie Shipp, Stephanie (Logsdon) Ward, Nancy Lin, Alisha George, Ryne Simpson, Ina St. Onge, Will Corwin, Grant Geigle, Alisha Hartmann, John Broderick, Stanley Szefler, Naomi Miyazawa, Brooke Tippin, Darci Anderson, Sonya Belimezova, Nidhya Navanandan, Tanya Watson, Michelle Olson, Wanda Caldwell, Caroline Horner, Lila Kertz, Tina Norris, Katherine Rivera-Spoljaric, Andrea Coverstone, Molly McDowell, Sarah Laughlin, Gina Laury, Rosanne Donato, Elizabeth Beckett-Firmage, Elia A. Cornidez, Silvia Lopez, Michele Simon, Raymond Skeps, Monica Vasquez, Rob Gage, Heather Shearer, Melissa Pecak, Sandi Winters, Christine Rukasin, Bernadette McNally, Darcy Johnson, Brian Vickery, Jocelyn Grunwell, Morgan Nicholls, Taqwa El-Hussein, Shilpa Patel, Dinsesh Pillai, Melanie Makhija, Rachel Robison, Jennifer Bosworth, Michelle Catalano, Kathleen Cassin, Laura Bamaca DeLeon, Nicole Titus, Sydney Leibel, Seema Aceves, Diba Mortazavi, Lauren Loop, Sara Anvari, Aikaterini Anagnostou, Kathy Pitts, Sopar Sebutra, Daisy Tran, Chivon McMullen-Jackson, Jay Jin, Nadia Krupp, Clement Ren, Girish Vitalpur, Lori Shively, Patrick Campbell, Lisa Bendy, Lisa France, Sylvia Jara, Sarah Cichy, Linda Engle, Aimee Merchlinski, Melanie Payton, Pam Ramsey, James Schmidt, Dan Tekely, Angela Updegrave, Rachel Weber, Ronald Zimmerman, Nervana Metwali, Xuefang Jing, Melissa Walker, Steven S. Sigelman, Ling Li, and Sanaz Hamrah
- Subjects
Allergy ,Omalizumab ,medicine.disease_cause ,Immunoglobulin E ,Antibodies, Monoclonal, Humanized ,Article ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,immune system diseases ,medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Anti-Asthmatic Agents ,Risk factor ,Child ,Sensitization ,Asthma ,030505 public health ,biology ,business.industry ,Antibodies, Monoclonal ,General Medicine ,medicine.disease ,respiratory tract diseases ,medicine.anatomical_structure ,Immunology ,biology.protein ,Rhinovirus ,0305 other medical science ,business ,medicine.drug - Abstract
Asthma remains one of the most important challenges to pediatric public health in the US. A large majority of children with persistent and chronic asthma demonstrate aeroallergen sensitization, which remains a pivotal risk factor associated with the development of persistent, progressive asthma throughout life. In individuals with a tendency toward Type 2 inflammation, sensitization and exposure to high concentrations of offending allergens is associated with increased risk for development of, and impairment from, asthma. The cascade of biological responses to allergens is primarily mediated through IgE antibodies and their production is further stimulated by IgE responses to antigen exposure. In addition, circulating IgE impairs innate anti-viral immune responses. The latter effect could magnify the effects of another early life exposure associated with increased risk of the development of asthma – viral infections. Omalizumab binds to circulating IgE and thus ablates antigen signaling through IgE-related mechanisms. Further, it has been shown restore IFN-α response to rhinovirus and to reduce asthma exacerbations during the viral season. We therefore hypothesized that early blockade of IgE and IgE mediated responses with omalizumab would prevent the development and reduce the severity of asthma in those at high risk for developing asthma. Herein, we describe a double-blind, placebo-controlled trial of omalizumab in 2–3 year old children at high risk for development of asthma to prevent the development and reduce the severity of asthma. We describe the rationale, methods, and lessons learned in implementing this potentially transformative trial aimed at prevention of asthma.
- Published
- 2020
5. A randomized, controlled study of insulin pump therapy in diabetic preschoolers
- Author
-
Linda A. DiMeglio, Tina M. Pottorff, Sheryl R. Boyd, Lisa France, Naomi Fineberg, and Erica A. Eugster
- Subjects
Insulin pump ,medicine.medical_specialty ,Randomization ,Diabetic ketoacidosis ,business.industry ,Insulin ,medicine.medical_treatment ,Hypoglycemia ,medicine.disease ,Surgery ,law.invention ,Randomized controlled trial ,law ,Diabetes mellitus ,Internal medicine ,Pediatrics, Perinatology and Child Health ,medicine ,business ,Glycemic - Abstract
Objective To compare glycemic control, safety, and parental satisfaction in preschool-aged diabetic children randomized to treatment either with continuous subcutaneous insulin infusion (CSII) or intensive insulin injection therapy. Study design This clinical trial enrolled 42 patients Results Thirty-seven patients completed 6 months of therapy. There was a significant decrease in HbA1c during the study period for both groups (from 8.9% ± 0.6% to 8.6% ± 0.6% at 3- and 6-month visits). At 3 months, children using pumps had a significantly lower HbA1c than the injection group (8.4% vs 8.8%); however, by 6 months the two groups were similar (8.5% vs 8.7%). No differences in pre-meal blood sugar variabilities were seen between groups. Children on pumps had increases in the number of meter-detected episodes of hypoglycemia. Pump therapy was safe and well tolerated. No episodes of ketoacidosis occurred in either group, whereas one hypoglycemic seizure occurred in each group. Parents reported satisfaction with CSII, with 95% of families continuing on CSII beyond the 6-month study period. Conclusion Pump therapy in preschool-aged children was not associated with clinically significant differences in glycemic control as compared with intensive injection therapy. The rationale for initiating CSII in this age group should be based on patient selection and lifestyle preference.
- Published
- 2004
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.